{
    "clinical_study": {
        "@rank": "138082", 
        "brief_summary": {
            "textblock": "To evaluate the safety and efficacy of azithromycin in the treatment of intestinal\n      cryptosporidial infection in AIDS patients."
        }, 
        "brief_title": "Azithromycin in the Treatment of Cryptosporidiosis in Patients With Acquired Immune Deficiency Syndrome (AIDS): A Randomized, Multi-Center, Placebo-Controlled, Double-Blind Study", 
        "condition": [
            "Cryptosporidiosis", 
            "HIV Infections"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Acquired Immunodeficiency Syndrome", 
                "HIV Infections", 
                "Cryptosporidiosis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Concurrent Medication:\n\n        Allowed:\n\n          -  Zidovudine.\n\n          -  Antidiarrheal medication with imodium or paregoric only.\n\n        Patients must have:\n\n          -  HIV infection.\n\n          -  Intestinal cryptosporidiosis proven by stool microscopy on at least two occasions\n             prior to study enrollment.\n\n          -  Life expectancy of at least 2 weeks by clinical assessment. In states where the legal\n             age of consent for medical procedures is 21 years, patients below the age of 21 must\n             have consent of parent or guardian.\n\n        Prior Medication:\n\n        Allowed:\n\n          -  Zidovudine.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following symptoms and conditions are excluded:\n\n          -  Known hypersensitivity or significant intolerance to macrolide antibiotics.\n\n          -  Marked abnormalities of liver or renal function.\n\n          -  Causes for diarrhea other than, or in addition to, cryptosporidiosis.\n\n          -  Inability to receive oral medication.\n\n        Concurrent Medication:\n\n        Excluded:\n\n          -  Cancer chemotherapy (including therapy for Kaposi's sarcoma).\n\n          -  Any drug or biologic preparation (e.g., bovine colostrum, paromomycin, spiramycin,\n             somatostatin) with possible anticryptosporidial activity.\n\n          -  Immunostimulant or lymphocyte replacement therapy.\n\n        Prior Medication:\n\n        Excluded:\n\n          -  Another investigational drug within 7 days prior to study enrollment (investigational\n             medications available through a treatment IND will be allowed with the approval of\n             the sponsor, the treatment IND sponsor, and the Pfizer clinical monitor).\n\n          -  Immunostimulant or lymphocyte replacement therapy.\n\n          -  Cancer chemotherapy (including therapy for Kaposi's sarcoma).\n\n        Not expected to comply with the requirements of the protocol, in the opinion of the\n        investigator."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002082", 
            "org_study_id": "058F", 
            "secondary_id": "066-143"
        }, 
        "intervention": {
            "intervention_name": "Azithromycin", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Azithromycin"
        }, 
        "keyword": [
            "Cryptosporidiosis", 
            "Acquired Immunodeficiency Syndrome", 
            "Azithromycin"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Oakland", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94609"
                    }, 
                    "name": "Infectious Disease Med Group"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Diego", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92103"
                    }, 
                    "name": "UCSD Med Ctr"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10021"
                    }, 
                    "name": "Cornell Univ Med Ctr"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Memphis", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "38103"
                    }, 
                    "name": "Univ of Tennessee"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Azithromycin in the Treatment of Cryptosporidiosis in Patients With Acquired Immune Deficiency Syndrome (AIDS): A Randomized, Multi-Center, Placebo-Controlled, Double-Blind Study", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "N/A", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002082"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 1996"
    }, 
    "geocoordinates": {
        "Cornell Univ Med Ctr": "40.714 -74.006", 
        "Infectious Disease Med Group": "37.804 -122.271", 
        "UCSD Med Ctr": "32.715 -117.157", 
        "Univ of Tennessee": "35.15 -90.049"
    }
}